Following the lead of Strategy and Japan’s Metaplanet, Parataxis is bringing Wall Street’s Bitcoin treasury strategy to Korea with an $18 million takeover of Bridge Bio, signaling deeper institutional crypto penetration. In a press release on June 20, Parataxis Holdings…Following the lead of Strategy and Japan’s Metaplanet, Parataxis is bringing Wall Street’s Bitcoin treasury strategy to Korea with an $18 million takeover of Bridge Bio, signaling deeper institutional crypto penetration. In a press release on June 20, Parataxis Holdings…

Parataxis seals $18m deal to launch Bitcoin treasury on KOSDAQ

2025/06/20 22:11
2분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

Following the lead of Strategy and Japan’s Metaplanet, Parataxis is bringing Wall Street’s Bitcoin treasury strategy to Korea with an $18 million takeover of Bridge Bio, signaling deeper institutional crypto penetration.

In a press release on June 20, Parataxis Holdings LLC announced its acquisition of a controlling stake in Bridge Biotherapeutics for KRW 25 billion (about $18 million).

The deal, pending shareholder approval, will see the biotech outfit rebranded as Parataxis Korea, a publicly traded, Bitcoin (BTC)-native treasury company listed on South Korea’s KOSDAQ exchange. Edward Chin, Parataxis’ founder, and Andrew Kim, a partner at its affiliate Parataxis Capital, will join the board, with Kim stepping in as CEO.

Bitcoin’s corporate wave hits Korea

Parataxis Korea plans to deploy an institutional-grade Bitcoin treasury strategy built around disciplined capital allocation, governance transparency, and long-term accumulation.

According to Parataxis executives, the soon-to-be-renamed successor of Bridge Biotherapeutics will be structured as a hybrid to retain its biotech arm while adding a BTC-centric financial strategy layered on top. James Jungkue Lee, co-founder of Bridge Bio, will lead the core biotech business.

Parataxis is joining an established movement. The company points to Strategy’s massive 582,000 BTC treasury and Metaplanet’s 10,000 BTC holdings as successful precedents for their Korean venture.

And the trend is growing: according to Standard Chartered, at least 61 publicly listed firms not native to crypto have adopted Bitcoin treasury strategies in recent months, a number that has doubled since April, underscoring how BTC is emerging as an alternative, not speculative, reserve asset for established companies.

For all the enthusiasm, the strategy isn’t without risks. Charles Schwab’s recent analysis warns that companies overexposed to Bitcoin risk liquidity crunches if prices plummet. Standard Chartered estimates a drop below $90,000 could wipe out half of corporate BTC treasuries.

시장 기회
BIO Protocol 로고
BIO Protocol 가격(BIO)
$0,01794
$0,01794$0,01794
-0,49%
USD
BIO Protocol (BIO) 실시간 가격 차트
면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

$30,000 in PRL + 15,000 USDT

$30,000 in PRL + 15,000 USDT$30,000 in PRL + 15,000 USDT

Deposit & trade PRL to boost your rewards!